Integer Holdings Corporation (ITGR) is drawing attention from options traders due to high implied volatility in its Dec. 18, 2026 $65 Put options, suggesting market expectations for significant price movement. The company holds a Zacks Rank #3 (Hold) rating in the Medical-Instruments industry, with analyst consensus estimates remaining relatively stable around $1.65-$1.66 per share for the current quarter.

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed transactions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

In a comparison of two medical instruments stocks, Globus Medical (GMED) emerges as the superior value option over Integer (ITGR). GMED holds a Zacks Rank of #1 (Strong Buy) with improving earnings outlook, while ITGR has a Zacks Rank of #3 (Hold). GMED also demonstrates better valuation metrics with a forward P/E of 15.18 versus ITGR's 20.74, and a PEG ratio of 1.22 compared to ITGR's 2.40, earning GMED a Value grade of B versus ITGR's C.

Globus Medical (GMED) and Integer (ITGR) are compared as potential value investments in the medical instruments sector. GMED emerges as the superior value option with a Zacks Rank #1 (Strong Buy) rating, lower forward P/E ratio of 14.88 versus ITGR's 20.68, and a Value grade of B compared to ITGR's C grade. GMED also shows stronger earnings estimate revisions and more favorable valuation metrics across multiple indicators.

In a comparison of two medical instruments stocks, Globus Medical (GMED) emerges as the superior value option over Integer (ITGR). GMED holds a Zacks Rank #1 (Strong Buy) with a Value grade of B, featuring a lower forward P/E ratio of 16.86 and PEG ratio of 1.35. ITGR carries a Zacks Rank #3 (Hold) with a Value grade of C, posting a higher forward P/E of 20.55 and PEG ratio of 2.96. Based on valuation metrics and earnings outlook, GMED is positioned as the more attractive choice for value investors.

Halper Sadeh LLC, an investor rights law firm, is investigating three major corporate transactions for potential securities law violations and breaches of fiduciary duties. The investigations involve Supernus Pharmaceuticals' sale to Indivior, Integer Holdings' acquisition by KKR, and Bowhead Specialty Holdings' sale to American Family Mutual Insurance. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

Integer Holdings Corporation (NYSE: ITGR), a leading medical device CDMO, announced its participation in the Truist Securities 2026 MedTech Conference on June 16, 2026. Executive leadership will participate in a fireside chat, with live webcast available on the company's investor relations website.

Integer Holdings (ITGR) surged over 5% after Oppenheimer analyst Suraj Kalia upgraded the stock to 'outperform' with a $115 price target. The upgrade was driven by Integer's announcement of a strategic review, suggesting potential acquisition interest from private equity firms. As a contract development and manufacturing organization (CDMO) for medical devices, Integer's modest valuations and profitable niche make it an attractive takeover target.

The global medical device contract development and manufacturing organization (CDMO) market is expected to expand significantly at a CAGR of 13.12% from 2026 to 2033, driven by increased outsourcing by OEMs, demand for advanced connected devices, and the shift toward home care and minimally invasive treatments. CDMOs are becoming essential partners for managing regulatory complexities, reducing capital expenditure, and accelerating time-to-market.

Integer Holdings Corporation announced that independent Board Chair Pamela G. Bailey will not seek re-election at the May 20, 2026 Annual Meeting. Donald J. Spence, a director since 2016 and former CEO of Ebb Therapeutics and Lake Region Medical, will be appointed as the new independent Chair following the meeting.

Integer Holdings Corporation's stock has declined 28% over the past year. VP Corporate Controller Tom Thomas sold 825 shares worth $70,000 on March 13, 2026, representing 15.85% of his direct holdings. The article characterizes this as routine liquidity management rather than a loss of confidence. Despite revenue growth of 8% YoY to $1.85 billion in 2025, the company faces elevated leverage near 3.0x EBITDA, with investors focused on whether Integer can sustain margin expansion and balance sheet improvement.

Grabar Law Office is investigating securities fraud claims against four companies: ASP Isotopes for allegedly making false statements about uranium enrichment technology; Integer Holdings for overstating competitive position and concealing sales deterioration; Molina Healthcare for failing to disclose adverse medical cost trends; and Soleno Therapeutics for misrepresenting the safety profile of its drug candidate DCCR, which resulted in a patient death.